Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

PHASE3UnknownINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

May 31, 2001

Conditions
HIV Infections
Interventions
DRUG

Lopinavir/Ritonavir

DRUG

Ritonavir

DRUG

GW433908

Trial Locations (32)

10011

Gervais Frechette, New York

20037

Physicans Home Service, Washington D.C.

23298

Virginia Commonwealth Univ, Richmond

27710

Duke Univ Med Ctr, Durham

30912

Med College of Georgia, Augusta

32503

Discovery Alliance Inc, Pensacola

32514

West Florida Clinical Research Ctr, Pensacola

32701

IDC Research Initiative, Altamonte Springs

32801

Florida ID Group, Orlando

33306

Community Health Care, Fort Lauderdale

33308

Therafirst Med Ctr, Fort Lauderdale

33311

North Broward Hosp District / HIV Clinical Research, Fort Lauderdale

34205

Bach and Godofsky, Bradenton

38104

Methodist Healthcare, Memphis

44304

Summa Health System, Akron

55404

Abbott-Northwestern Hosp / Clinic 42, Minneapolis

60612

Rush Med College / Dept of Infectious Diseases, Chicago

63139

Southampton Healthcare Inc, St Louis

77004

Joseph Gathe, Houston

80220

Denver Inf Disease Consultants, Denver

85006

Phoenix Body Positive, Phoenix

90046

Bisher Akil, Los Angeles

90048

Tower ID Med Associates, Los Angeles

90803

Ocean View Internal Medicine, Long Beach

92663

Orange Coast Med Group, Newport Beach

94115

Pacific Horizons Med Group, San Francisco

97219

Fanno Creek Clinic, Portland

021182393

Boston Med Ctr / Evans - 556, Boston

08244

South Jersey Infectious Diseases Inc, Somers Point

08876

ID Care Inc, Somerville

08043

Garden State Infectious Diseases / E I P Kennedy Health Sys, Voorhees Township

02908

Roger Williams Med Ctr, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00025727 - Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure | Biotech Hunter | Biotech Hunter